Intermediate class of drugs has potential to affect cost and availability, GAO report says.
This article was originally published in The Tan Sheet
Executive Summary
PHARMACY-CLASS OF DRUGS HAS POTENTIAL TO AFFECT DRUG COSTS, AVAILABILITY, the General Accounting Office speculated in a report released on Aug. 24. The establishment of a third class of drugs in the U.S. "could affect the price and availability of drugs to consumers and might also alter the revenues or profits of both manufacturers and retailers," the GAO cautioned.